Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. Its product candidate include cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. The company has license agreements with Sopharma AD and University of Bristol; and a strategic collaboration with National Institutes of Health for the development of cytisinicline for smoking cessation. Achieve Life Sciences, Inc. was incorporated in 1991 and is based in Vancouver, Canada.